MedTrace Logo

Positron Nuclide Labeled NOTA-FAPI PET Study in Lymphoma

NCT04367948 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 200

Last updated 2020-04-29

No results posted yet for this study

Summary

To evaluate the normal physiological distribution of positron nuclide labeled NOTA-F API in human body and its detection efficiency for lymphoma

Conditions

  • Tumor, Solid
  • Positron-Emission Tomography
  • Lymphoma

Interventions

DIAGNOSTIC_TEST

18F-FDG and 68Ga-NOTA-FAPI04 PET/CT

Each subject receive a single intravenous injection of 18F-FDG and 68Ga-NOTA-FAPI04, and undergo PET/CT imaging within the specified time

DIAGNOSTIC_TEST

18F-FDG and 18F-NOTA-FAPI04 PET/CT

Each subject receive a single intravenous injection of 18F-FDG and 18F-NOTA-FAPI04, and undergo PET/CT imaging within the specified time

Sponsors & Collaborators

  • Peking University Cancer Hospital & Institute

    lead OTHER

Principal Investigators

  • Zhi Yang, PhD · Peking University Cancer Hospital & Institute

Study Design

Allocation
RANDOMIZED
Purpose
DIAGNOSTIC
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-05-01
Primary Completion
2021-12-31
Completion
2022-12-31

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04367948 on ClinicalTrials.gov